SHILPA MEDICARE LTD

Shilpa Medicare Limited held its Q1 FY27 earnings conference call on August 5, 2026, where management highlighted significant improvements in the company's financial health. CEO Keshav Bhutada reported a net debt-to-EBITDA ratio of 1.3x and a double-digit ROCE, emphasizing a shift from a debt-laden API business to a more diversified portfolio focused on complex drug development. The company achieved its highest-ever quarterly revenue of INR 469 crores, a 43% year-on-year increase, with an EBITDA of INR 139 crores. The API division showed steady growth, while the Formulation division benefited from successful product launches, including Nor-UDCA. The Biologics division is also on track, with plans for multiple product launches. CFO Alpesh Dalal noted a credit rating upgrade to AA- and a commitment to maintaining strong operating margins despite global raw material price pressures. The call concluded with management expressing confidence in future growth and thanking investors for their support.

Management emphasized strong financial performance and growth potential across divisions.